Biography
Allan is a pharmacometrician and postdoctoral scholar at the Infectious Diseases Institute in Kampala, Uganda. He is a PhD candidate in pharmacometrics at the University of Cape Town, South Africa. His research focused on pharmacokinetic modeling to optimize dosing strategies and enhance treatment outcomes for tuberculosis and HIV. Allan contributed to the population pharmacokinetic analysis of data from the TRUNCATE-TB trial, supporting efforts to shorten TB therapy.
Key Impacts
Clofazimine pharmacokinetics in shorter treatment regimens for drug-sensitive TB
CFZ clearance was lower and elimination half-life longer than previously-published estimates. Concentrations likely persist at potentially-efficacious levels for a prolonged period after completion of an 8-week treatment regimen.
Source: Conference 2024
Safety and hepatotoxicity profile of 3HP for TB preventive therapy among people living with HIV in Uganda
3HP was generally well-tolerated with low discontinuation rates among PLWH in the programmatic setting in Uganda.
Source: Conference 2024